Renal Cancer - Results from #5680

Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma July 1, 2016

Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types July 1, 2016

Occurrence of renal cell carcinoma and hematologic malignancies (predominantly lymphoid) in individuals and in families July 1, 2016

Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 1 - kidney cancer June 30, 2016

Expression and clinicopathological correlations of retinoid acid receptor responder protein 1 in renal cell carcinomas June 29, 2016

Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma June 29, 2016

Role of mTOR Inhibitors in Kidney Disease June 28, 2016

Complete metastasectomy for renal cell carcinoma: Comparison of five solid organ sites June 28, 2016

Application of the Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear Cell Renal Cell Carcinoma in Contemporary Patients June 27, 2016

A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma June 27, 2016

Racial disparities in survival among patients with advanced renal cell carcinoma in the targeted therapy era June 27, 2016

Alcohol and Dietary Folate Intake and Promoter CpG Island Methylation in Clear-Cell Renal Cell Cancer June 27, 2016

iTRAQ-based quantitative proteomic analysis reveals potential early diagnostic markers of clear-cell Renal cell carcinoma June 26, 2016

Survival Analyses of Metastatic Renal Cancer Patients Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study June 26, 2016

Resection of metastasis and local recurrences of renal cell carcinoma after presurgical targeted therapy: probability of complete local control and outcome June 24, 2016

Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials June 24, 2016

[Immune Checkpoint for a Kidney Cancer and Other Cancers] June 23, 2016

[Social medicine assessment after surgical and targeted treatment of renal cell cancer] June 23, 2016

Renal Carcinogenesis, Tumor Heterogeneity, and ROS: The Devil wears Prada June 23, 2016

Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity June 23, 2016

Page 285 of 459